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Abstract To determine the relationship between clinical
presentation, radiographic features, pathology, and treat-
ment on overall survival of newly diagnosed pediatric pri-
mary spinal cord tumors (PSCT). Retrospective analysis of
all previously healthy children with newly diagnosed PSCT
at a single institution from 1995 to present was performed.
Twenty-ﬁve pediatric patients (15 boys, average 7.9 years)
were diagnosed with PSCT. Presenting symptoms ranged
from 0.25 to 60 months (average 7.8 months). Symptom
duration was signiﬁcantly shorter for high grade tumors
(average 1.65 months) than low grade tumors (average
11.2 months) (P = 0.05). MRI revealed tumor (8 cervical,
17 thoracic, 7 lumbar, 7 sacral) volumes of 98–94,080 mm
3
(average 19,474 mm
3). Homogeneous gadolinium enhance-
ment on MRI correlated with lower grade pathology
(P = 0.003). There was no correlation betweentumor grade
and volume (P = 0.63) or edema (P = 0.36) by MRI
analysis. Median survival was 53 months and was depen-
dent on tumor grade (P = 0.05) and gross total resection
(P = 0.01) but not on gender (P = 0.49), age of presenta-
tion (P = 0.82), duration of presenting symptoms (P =
0.33), or adjuvant therapies (P = 0.17). Stratiﬁed Kaplan–
Meier analysis conﬁrmed the association between degree of
resection and survival after controlling for tumor grade
(P = 0.01). MRI homogeneous gadolinium enhancement
patterns may be helpful in distinguishing low grade from
highgrade spinal cord malignancies. Whiletumor grade and
gross total resection rather than duration of symptoms cor-
related with survival in our series, greater than one-third of
patients had reported symptoms greater than 6 months
duration prior to diagnosis.
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Introduction
Primary spinal cord tumors (PSCT) are rare central ner-
vous system (CNS) neoplasms in childhood that occur at
a frequency of 0.19 per 100,000 person-years according
to the Central Brain Tumor Registry of the United States
[1]. The incidence varies by age, and increases 1.6 times
from 0–4 years old (0.17 per 100,000 person-years) to
ages 15–19 (0.28 per 100,000 person-years) [1]. Pediatric
PSCT account for \6% of all CNS tumors [2], and have
a roughly similar male to female predominance [3–5].
The initial approach to diagnosis and management of
PSCT has been extensively reviewed [2, 6, 8–21] and is
dependent on anatomical location (intramedullary, extra-
medullary intradural, and extradural) and pathology.
Much of our understanding of the clinical presentation,
diagnosis, treatment, and survival features of PSCT
comes from small series of patients due to the low
incidence. A few larger series of combined multi-insti-
tutional PSCT patients have been reported according to
speciﬁc tumor type [2, 17, 22]. Several smaller pediatric
series of PSCT have been published correlating presen-
tation, treatment, and tumor histology with event free and
overall survival [10, 12, 13, 18, 20, 23–27]. To our
knowledge, no series has speciﬁcally attempted to cor-
relate duration of symptoms, neurological examination
abnormalities, and speciﬁc neuroradiographic features
with malignancy and overall survival. To address these
issues, we have performed a retrospective analysis of all
previously healthy pediatric patients seen at our institu-
tion from 1995 to present with newly diagnosed PSCT.
The diverse presentations, duration of symptoms, radio-
graphic ﬁndings, and outcomes presented in our series
expands our current knowledge of this rare pediatric
neoplasm.
Methods
Clinical information
All spinal cord tissue specimens at Children’s National
Medical Center in Washington, DC, from 1995 to present
were available for retrospective analysis and approved by
the Institutional Review Board. A total of 45 patients were
identiﬁed with spinal cord lesions diagnosed between 1995
and present. Neurodevelopmental tumors (dermoids, epi-
dermoids, and teratomas), lesions associated with tethered
cord (lipomas, ﬁbrous bands, hemartomatous tissue, and
ﬁbrolipomatosis), sacrococcygeal teratomas, epidermoid
cysts, and tumors related to neuroﬁbromatosis Type 1 or
Type 2 were excluded from the study. Patients with non-
PSCT (i.e. drop metastasis from brain neoplasms) were
excluded from the analysis. No patients in our study had
meningiomas or schwanommas that were not associated
with Neuroﬁbromatosis. Of the 45 total spinal cord sam-
ples, 25 patients were diagnosed with PSCT and were
available for analysis. Information including age, sex,
presenting symptoms, duration of symptoms, neurological
examination, and treatment were collected and utilized in
the overall clinical analysis.
Neuroradiographic investigation
Standard MRI sequences of pediatric spinal cord tumors
using a 1.5-T magnet were reviewed by three non-blinded
pediatric neuroradiologists (NK, AZ, and GV). Of the 25
patients with available clinical information, 20 patients
had complete imaging studies available for analysis. The
following neuroimaging features were used for quantita-
tive analysis: tumor location, size, contrast enhancement,
and presence of edema. Tumor volume was measured in
depth, height, and width. Volume (mm
3) was calculated
as: depth 9 height 9 width 9 0.5 and grouped in sub-
categories of small (B1,000 mm
3), medium (1,001–
9,999 mm
3), and large (C10,000 mm
3) for statistical
analysis.
Pathological investigation
All pathology diagnosis were made by a pediatric neuro-
pathologist. Select cases used for the clinical and radio-
graphic analysis were re-reviewed by two pediatric
neuropathologists (MS, EJR). Hematoxylin and eosin
stained sections were re-reviewed as were other routine
histochemical and immunohistochemical preparations.
Neoplasms were classiﬁed and graded based on World
Health Organization criteria.
Statistical analysis
Data were analyzed using Fisher’s exact test to compare
proportions, and t-test for independent samples to compare
means. Kaplan–Meier Survival and ANOVA analysis were
performed using GraphPad 5.0 Software (San Diego, CA).
Stratiﬁed Kaplan–Meier analysis was performed using
SPSS software (Chicago IL).
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123Results
Clinical features of primary spinal cord tumors
of childhood
We retrospectively reviewed the records of 25 consecutive
pediatric patients seen at a single institution from 1995 to
present newly diagnosed with PSCT. As summarized in
Table 1, the average age at presentation was 7.9 months
(range 1–5 years; 15 boys). Thoracic cord was the most
commonly involved location (N = 17) followed by cervical
(N = 9), lumbar (N = 7), and sacral/cauda equina (N = 7).
The most common presenting features were back pain (15/
25) and weakness (13/25). In children less than 3 years old,
head tilt, delayed motor milestones, and early handedness
were the predominant presenting symptoms. There was no
difference between age of presentation and symptoms of
pain and weakness (P = 0.17), however, speciﬁc neck
complaints including pain, weakness, rigidity, or tremor
were signiﬁcantly observed in younger patients (average
2.5 years; range 1.5–5 years) (P = 0.05). The average
reported duration of symptoms was 7.8 months, ranging
from 1 week (acute lower extremity pain/weakness) to
5 years (chronic low back pain). There was no signiﬁcant
differencebetweendurationofsymptomsandsymptomtype
(P = 0.06),butearlyhandednessandbackpainwerepresent
the longest prior to diagnosis (Fig. 1). There was no corre-
lation between symptom duration and age of presentation
(P = 0.95).Whenstratiﬁedaccordingtospeciﬁcagegroups
(0–3 years, 4–12 years, and 13–18 years) duration of
symptoms were not different (P = 0.11). Boys had a longer
reported duration of symptoms prior to diagnosis than girls
(11.3 vs. 2.9 months) (P = 0.03). While there was no cor-
relation between length of presenting symptoms and ana-
tomical location (P = 0.30), there was a difference between
length of symptoms and tumor grade. Patients with high
grade tumors had a shorter duration of symptoms (average
1.65 months, range 0.25–7 months) than patients with low
grade tumors (average 11.1 months, range 0.25–60 months)
(P = 0.05). There was no difference between tumor grade
and age (P = 0.71) or gender (P = 0.10). The most com-
mon neurological abnormality was change in muscle tone or
strength, followed by abnormal reﬂexes (7 hyper, 9 hypo/
absent). Four patients had evidence of a sensory level on
examination along with hypo or absent reﬂexes, mimicking
transverse myelitis or Guillain Barre ´ syndrome.
Neuroradiographic analysis of primary spinal
cord tumors of childhood
We performed a detailed neuroradiographic analysis
including tumor volume, T1/T2 signal characteristics,
gadolinium enhancement patterns, and the presence of
edema in 20 patients with newly diagnosed PSCT who had
sufﬁcient image sequences for interpretation. Typical and
atypical neuroradiographic features of spinal cord astro-
cytomas and ependymomas, the most common tumors in
our series, are illustrated in Fig. 2. As summarized in
Table 2, the most common spinal tumor location was
intramedullary (N = 11) followed by extramedullary
intradural (N = 8) and epidural (N = 1). Eighty percent
(4/5) of ependymomas analyzed in our series had an
extramedullary component; half of which had multiple
lesions. Quantitative volumetric analysis revealed ranges
from 98 to 94,080 mm
3 (average 19,474 mm
3). There was
no difference between low grade tumor volume (average
19,868 mm
3) and high grade tumor volume (average
15,676 mm
3)( P = 0.63) at the time of diagnosis. When
stratifying for evidence of edema (illustrated in Fig. 3),
there was no correlation with tumor grade (P = 0.22).
Fig. 1 Average duration of
symptoms of primary spinal
cord tumors (PSCT) of
childhood. The average duration
of neurological complaints of
PSCT is shown. There was no
signiﬁcant difference between
speciﬁc symptom type and
duration by ANOVA analysis
(P = 0.063)
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123Likewise, neither T2 hyperintensity (P = 1.0) nor T1
hypointensity (P = 0.11) were signiﬁcantly associated
with grade. Homogeneous gadolinium enhancement was
found signiﬁcantly more in low grade tumors (P = 0.003).
Rim gadolinium enhancement, on the other hand, did not
correlate with tumor grade (P = 0.098).
Effects of symptomatology and treatment on survival
The median overall survival of our series of PSCT was
53 months (range 1.5–53 months; 10 deaths) with a med-
ian follow up 21 months (Fig. 4). Despite the earlier pre-
sentation of girls in our series, there was no affect of
Fig. 2 MRI characteristics of glial and ependymal primary spinal
cord tumors (PSCT). Top panel a Pediatric spinal cord astrocytomas.
A–E Pilocytic astrocytoma. Note the wide variability of imaging
features. All lesions A–E are well-deﬁned on T2 (T1)-weighted
images. Only A and E have appearance of nodular enhancement in
conjunction with a cyst, no cysts are seen in lesions B, C, D. The
enhancement patterns vary from irregular (A, E), homogeneous (B),
no signiﬁcant enhancement (C) to rim-enhancement (D), the latter
usually more typical of a higher grade lesions. F?G Fibrillary
astrocytoma. These lesions share a pattern of sausage-like expansion
of the spinal cord, similar to pilocytic astrocytoma C, but with diffuse
contrast enhancement. Edema of the adjacent spinal cord is only seen
in lesion F. H?I Anaplastic (H) and high-grade (I) astrocytoma. Both
high grade astrocytomas are rim-enhancing; edema of the adjacent
spinal cord is more prominent in I when compared to H. Bottom panel
b. Pediatric spinal cord ependymoma. Sagittal T1, T2, and axial T2
are shown in A–C compared to a patient with myxopapillary
ependymoma in D. These lesions are only different in the T2
appearance (bright in patient D) and inhomogeneous contrast
enhancement in patient D. Interestingly, 2/5 patients presented with
multiple lesions (patients B?E)
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123gender on survival (Median survival 53 months boys;
41 months girls) (P = 0.58) (Fig. 4a). There was no cor-
relation between age of diagnosis and survival (P = 0.35),
nor was there a difference when stratiﬁed according to
speciﬁc age group (P = 0.79) (Fig. 4b). Duration of
symptoms did not affect overall survival; given the wide
range of presenting neurological symptoms. Those patients
with symptoms greater than 6 months had an average
survival of 48 months compared to 35 months for symp-
toms greater than 6 months (P = 0.91) (Fig. 4c). Of the 10
deaths in our series, the average time of presentation was
3.9 months compared to 10.4 months for those who sur-
vived (P = 0.08). As expected, patients with high grade
tumors (median survival 25 months) had signiﬁcantly
poorer survival than those with low grade tumors (median
survival 53 months) (P = 0.05) as shown in Fig. 4d. In
addition to having no correlation with tumor grade, tumor
volume did not correlate with overall survival in our series
(P = 0.13).
Compared to patients with biopsy or subtotal resection,
patients with gross total resection had 100% survival
(Fig. 4e) (P = 0.01). Thirty-six percent of patients in our
series had a gross total resection (9/25). Of these patients,
three had residual post operative weakness. Of the 25
patients with surgical intervention (gross/subtotal resec-
tion, biopsy) 10 had some degree of post operative weak-
ness, 8 of which resolved within months of surgery. The
most severe complication was the development of Brown-
Sequard syndrome in a patient with a lumbar sacral diffuse
ﬁbrillary astrocytoma.
Since non-surgical adjuvant treatments were not stan-
dardized, a generalized stratiﬁcation of chemotherapy,
radiation, or combined therapies were used for survival
analysis. Three of 25 patients had adjuvant chemotherapy
Table 2 Radiographic features of primary spinal cord tumors (PSCT) of childhood
Pathology Spinal
level
Tumor location Tumor volume
(mm3)
MRI signal
a Gadolinium
enhancement
Edema
T1 T2
1 Pilocytic astrocytoma C5–T1 Intramedullary 21,660 ; $ Irregular No
2 Pilocytic astrocytoma C1–C3 Intramedullary 12,000 $ ;: Homogenous No
3 Anaplastic ependymoma S2 Extramedullary
Intradural
2,211 ; $ Homogenous Yes
4 Anaplastic astrocytoma C2–C5 Intramedullary 11,832 ;; : Rim enhancing Yes
5 Langerhans cell histiocytosis T4 Epidural 11,160 $$Not performed No
6 Primitive neuroepithelial tumor T8–T12 Intramedullary 6,600 ;: ;: Irregular Yes
7 Primitive neuroectodermal tumor S3 Extramedullary
Intradural
1,056 $ ;: Not performed No
8 Primitive undifferentiated tumor T10–S1 Extramedullary
Intradural
13,520 ;; : Irregular Yes
9 Ependymoma L2–L3 Extramedullary
Intradural
11,856 ;:Homogenous No
10 Fibrillary astrocytoma C3–T1 Intramedullary 21,504 ;:Irregular No
11 Pilocytic astrocytoma C1–C7 Intramedullary 21,560 ;:Irregular Yes
12 Pilocytic astrocytoma C1–C5 Intramedullary 94,080 ;:Irregular No
13 Myxopapillary ependymoma L1–S1 Extramedullary
Intradural
21,630 ;:Irregular No
14 Pilocytic astrocytoma T7–T8 Intramedullary 98 $ ;: Homogenous No
15 Fibrillary astrocytoma T1–T6 Intramedullary 21,097 ;:Irregular Yes
16 Embryonal tumor C5–S2 Extramedullary Intradural 70,200 ; $ Irregular No
17 Ependymoma with
myxopapillary features
L2 Extramedullary
Intradural
2,736 ;:Irregular No
18 Glioblastoma multiforme C2–T2 Intramedullary 4,212 ;:Rim enhancing Yes
19 Ependymoma L3–L5 Intramedullary 4,920 ;:Homogenous No
20 Pilocytic astrocytoma C1–T1 Intramedullary 35,552 ;:Irregular Yes
C Cervical, T Thoracic, L Lumbar, S Sacral
a :, Hyperintense;;, hypointense; $, isointense
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123alone without evidence of relapse. Six of 25 had adjuvant
radiation therapy alone (two ﬁbrillary astrocytoma, one
anaplastic astrocytoma, one pilocytic astrocytoma, one
PNET, one myxopapillary ependymoma); of these two had
progressive disease. Combined radiation and chemotherapy
were used in 40% of patients (10/25), 90% of whom had
either metastatic disease at diagnosis or eventually had
progressive disease. As shown in Fig. 4f, adjuvant che-
motherapy and radiation either alone or in combination had
no signiﬁcant effect on overall survival (P = 0.31). While
the speciﬁc cause of death was not known for each of the
10 patients, 4 had complications secondary to pneumonia
and sepsis.
Discussion
The average duration of presenting symptoms of
7.8 months in our series of PSCT is similar to previous
reports ranging from 2 to 9 months [18, 21, 22]. Bouffet
et al. reported 11% (8/73) of patients with primary spinal
astrocytomas had greater than 3 years of symptoms prior to
presentation. While pain and weakness were the predomi-
nant presenting features in many patients, more subtle
ﬁndings such as early handedness can delay diagnosis
particularly in younger patients. A common set of pre-
senting complaints among younger patients in our series
involved the neck and included pain and torticollis, as has
been reported in two younger patients with PSCT [28]. In
older patients, chronic back pain has been associated with
delayed diagnosis of PSCT [22, 23], similar to our ﬁndings.
The variability of reﬂexes (hypo/hyper/absent) on neuro-
logical examination was not particularly helpful in estab-
lishing tumor location or grade compared to more sensitive
ﬁndings of tone and strength. Ultimately, duration of pre-
senting symptoms did not correlate with outcome as has
been reported [23]. However, shorter duration of symptoms
is associated with higher grade tumors in our series and has
been associated with poor survival in the series reported by
Bouffet et al. [22].
One of the strengths of the current study is the detailed
radiographic analysis performed on a subset of patients
where neuroimaging studies were complete. It seems
counterintuitive that there was no correlation between
tumor volume and tumor type, grade, or survival. This
suggests that tumor location itself as opposed to size may
be an important factor in achieving gross total resection
and hence improved survival. One set of factors that may
associated with spinal cord tumor grade are speciﬁc pat-
terns of gadolinium enhancement. Our observations of
homogeneous gadolinium enhancement associated with
low grade tumors has been reported [29]. However, in the
context of predictors of survival, this may be an important
ﬁnding. Due to our small number of patients studied, it is
difﬁcult to make generalizations. A multi-institutional
series of collaborative neuroradiographic data on PSCT is
ultimately necessary to validate our results.
One of the major factors associated with survival in our
series of PSCT was degree of surgical resection. While
35% of PSCT are intramedullary (65% in our series),
making total resection at times technically challenging, it is
a feasible option [7, 14, 30–33]. However, as reported in
our series, post operative complications, although tempo-
rary, can be associated with signiﬁcant morbidity. Radical
excision of intramedullary tumors has been reportedly
associated with both an increase in survival and improved
quality of life [6, 31–34], but are dependent on tumor type
and grade. Long term control or cure can be achieved for
some intramedullary ependymomas by total/subtotal
resection alone [9, 11, 17, 21]. This is in contrast to inﬁl-
trating astrocytomas where the role of subtotal resection is
less clear [4, 9, 17, 21, 31] but may be better than biopsy
alone [35]. Only through collaborative studies involving
Fig. 3 Detection of spinal cord tumor-related edema on MRI.
Examples of the presence or absence of edema in two cases of
pilocytic astrocytoma are shown. a Edema present Note the small
central rim-enhancing lesions surrounded by bright T2 (top) and dark
T1 (bottom) signal, compatible with edema. b Edema absent Note
there is no increased T2 (top) or dark T1 (bottom) signal beyond the
well-deﬁned border of this lesion
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123large number of patients will we be able to meaningfully
assess the extent of surgical resection on survival.
One of the major criticisms of the current study in
addition to the small sample size and retrospective study
design, is the lack of uniformity of adjuvant therapies.
While neither chemotherapy nor radiation alone or in
combination affected overall survival in our series, there
remains great debate regarding the role of adjuvant
therapies in PSCT. There are some who avoid adjuvant
therapy in cases of total resection [36, 37]. In the case of
radiation therapy, favorable outcome results have been
reported in patients with low grade spinal astrocytomas
and ependymomas [38–44]. However, in patients with
low grade astrocytomas with incomplete resection,
the role of radiation therapy is unclear [22]. With regards
to adjuvant chemotherapy, there is no proven efﬁca-
cious regimen for any given pathological subtype or
location.
A major hurdle in our understanding of PSCT, is a
lack of fundamental knowledge of the biology of the
tumor. It is naı ¨ve to assume the biological pathways that
govern oncogenesis in the brain can be applied to the
spinal cord. Furthermore, small amounts of tissue
obtained during biopsy or resection can limit the number
of non standard genetic/biochemical tests necessary to
fully understand the biology of the tumors. While for-
tunately the incidence if PSCT is quite low, the mortality
associated with PSCT calls for a more collaborative
approach to our understanding and treatment of pediatric
spinal cord tumors.
Fig. 4 The effects of
symptomatology, tumor grade,
and treatment on overall
survival of pediatric primary
spinal cord tumors. Kaplan–
Meier survival analysis was
stratiﬁed according to gender
(a), age (b), duration of
symptoms (c) tumor grade (d),
extent of resection (e), and
adjuvant therapies (f). There
was no correlation between
overall survival and gender
(P = 0.58), age (P = 0.79), or
duration of symptoms greater or
less than 6 months (P = 0.91).
High grade malignancy was
associated with poorer survival
(P = 0.05) as was gross total
resection (P = 0.01). Adjuvant
chemotherapy and radiation
therapy, either alone or in
combination, had no effect on
overall survival in our series
(P = 0.31)
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